- Home
- DRH vs DNTH Comparison
DRH vs DNTH Comparison
Compare DRH & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRH
- DNTH
- Stock Information
- Founded
- DRH 2004
- DNTH 2015
- Country
- DRH United States
- DNTH United States
- Employees
- DRH N/A
- DNTH N/A
- Industry
- DRH Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- DRH Real Estate
- DNTH Health Care
- Exchange
- DRH Nasdaq
- DNTH Nasdaq
- Market Cap
- DRH 1.7B
- DNTH 1.5B
- IPO Year
- DRH 2005
- DNTH N/A
- Fundamental
- Price
- DRH $7.77
- DNTH $34.50
- Analyst Decision
- DRH Hold
- DNTH Strong Buy
- Analyst Count
- DRH 6
- DNTH 10
- Target Price
- DRH $8.63
- DNTH $66.38
- AVG Volume (30 Days)
- DRH 3.0M
- DNTH 947.1K
- Earning Date
- DRH 11-06-2025
- DNTH 11-06-2025
- Dividend Yield
- DRH 4.11%
- DNTH N/A
- EPS Growth
- DRH N/A
- DNTH N/A
- EPS
- DRH 0.28
- DNTH N/A
- Revenue
- DRH $1,124,753,000.00
- DNTH $4,854,000.00
- Revenue This Year
- DRH N/A
- DNTH N/A
- Revenue Next Year
- DRH $2.31
- DNTH N/A
- P/E Ratio
- DRH $27.94
- DNTH N/A
- Revenue Growth
- DRH 1.72
- DNTH 17.87
- 52 Week Low
- DRH $6.19
- DNTH $13.37
- 52 Week High
- DRH $10.00
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- DRH 32.82
- DNTH 50.57
- Support Level
- DRH $7.87
- DNTH $33.96
- Resistance Level
- DRH $8.08
- DNTH $40.16
- Average True Range (ATR)
- DRH 0.14
- DNTH 2.12
- MACD
- DRH -0.05
- DNTH -0.97
- Stochastic Oscillator
- DRH 0.00
- DNTH 4.03
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.